Phase 3 Readout~month

Phase 3 Topline: A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-

Name: Phase 3 Topline: A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-
Start: 2027-10-16

October 16, 2027

Company: Immunocore Holdings plc (IMCR)
Drug: imc-f106c
Indication: Advanced Melanoma

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start Free Full Calendar

Phase 3 Topline: A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA- — IMCR Phase 3 Readout | BioSniper